[Comment] Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?

With an increasing number of available drugs along with a focus on early treatment regimens and drug sequencing in Crohn's disease, data from prospective, well designed studies to guide on drug choice are highly needed yet remarkably scarce.1,2 To this end, the final results of LOVE-CD, a phase 4 investigator-initiated, open-label study by Geert D'Haens and colleagues3 published in The Lancet Gastroenterology & Hepatology, represent a timely and relevant contribution aiming to clarify the clinical question of the efficacy and safety of vedolizumab in early versus late Crohn's disease.